| Identification | Back Directory | [Name]
Propanoic acid, 2-hydroxy-, compd. with N-[(2E)-6,6-dimethyl-2-hepten-4-ynyl]-N-methyl-1-naphthalenemethanamine (1:1) | [CAS]
335276-86-3 | [Synonyms]
DRG-0286
Lamisil Krem
Terbinafine lactate
SF 86-327 hydrochloride
Propanoic acid, 2-hydroxy-, compd. with N-[(2E)-6,6-dimethyl-2-hepten-4-ynyl]-N-methyl-1-naphthalenemethanamine (1:1) | [Molecular Formula]
C24H31NO3 | [MOL File]
335276-86-3.mol | [Molecular Weight]
381.52 |
| Hazard Information | Back Directory | [Description]
Terbinafine is a synthetic allylamine antifungal, is used topically for skin infections. Terbinafine hydrochloride is a white fine crystalline powder that is freely soluble in methanol and dichloromethane, soluble in ethanol, and slightly soluble in water. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting squalene epoxidase, an enzyme that is part of the fungal cell membrane synthesis pathway. Because terbinafine prevents conversion of squalene to lanosterol, ergosterol cannot be synthesized. This is thought to change cell membrane permeability, causing fungal cell lysis. (last updated: 8/11/2016). | [Uses]
Terbinafine lactate (TDT 067 lactate) is an orally active and potent antifungal agent. Terbinafine lactate is a potent non-competitive inhibitor of squalene epoxidase from Candida, with a Ki of 30 nM. Terbinafine lactate also shows antibacterial activity against certain Gram-positive and Gram-negative bacteria[1][2][3]. Terbinafine (lactate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | [in vivo]
Terbinafine is not only active after topical application but is very effective in experimental dermatophytoses following oral administration. In fungi infected guinea-pigs, the skin temperature dropps dramatically after the fourth treatment of terbinafine[2]. | [References]
[1] Ryder NS, et al. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992 Feb;126 Suppl 39:2-8. DOI:10.1111/j.1365-2133.1992.tb00001.x
[2] Mieth H, et al. Preclinical evaluation of terbinafine in vivo. Clin Exp Dermatol. 1989 Mar;14(2):104-8. DOI:10.1111/j.1365-2230.1989.tb00903.x
[3] Ciftci E, et al. Mupirocin vs terbinafine in impetigo.Indian J Pediatr. 2002 Aug;69(8):679-82. DOI:10.1007/BF02722704 |
|
|